J&J-Guidant Merger Spotlights Stent Patent Wars

Law360, New York (November 15, 2005, 12:00 AM EST) -- Johnson & Johnson’s pending $21.5 billion acquisition of Guidant, one of the largest mergers in the history of the medical device industry, puts the spotlight on the intense legal battle over the lucrative patents to drug-coated stents, attorneys say.

J& J and Guidant are active worldwide in vascular medical devices, with their products used to treat diseases within the heart, as well as other parts of the body.

Before the two companies began discussing the merger, they were on opposite sides of the courtroom disputing heart...
To view the full article, register now.